Analyst Rating Update on Apricus Biosciences Inc (APRI)

Apricus Biosciences Inc (APRI) : Zacks Investment Research ranks Apricus Biosciences Inc (APRI) as 3, which is a Hold recommendation. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 2 research analysts is 2.5, which indicates as a Buy.

Apricus Biosciences Inc (APRI) : Currently there are 2 street experts covering Apricus Biosciences Inc (APRI) stock. The most bullish and bearish price target for the stock is $3 and $1 respectively for the short term. The average price target of all the analysts comes to $1.73. The estimated standard deviation from the target is $1.73.

For the current week, the company shares have a recommendation consensus of Buy.


Apricus Biosciences Inc (NASDAQ:APRI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.31 and $0.31 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.33, notching a gain of 6.62% for the day. The total traded volume was 851,042 . The stock had closed at $0.31 on the previous day.

Apricus Biosciences, Inc. is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Companys drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe. The Companys other pipeline includes RayVa, Fispemifene and Femprox. RayVa utilizes the Companys permeation enhancer for the treatment of Raynauds phenomenon secondary to scleroderma. Fispemifene a tissue-specific selective estrogen receptor modulator (SERM) used for the treatment of secondary hypogonadism. Femprox is used for the treatment of female sexual interest and arousal disorder (FSIAD). The Company owns or exclusively licenses approximately 331 issued patents and 194 patent applications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.